Belluscura (LSE:BELL) 12-1 Month Momentum %: -92.68% (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Belluscura 12-1 Month Momentum %?

Belluscura LSE:BELL 12-1 Month Momentum % is -92.68% as of Aug. 30, 2026.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-30), Belluscura's 12-1 Month Momentum % is -92.68%.

The industry rank for Belluscura's 12-1 Month Momentum % or its related term are showing as below:

LSE:BELL's 12-1 Month Momentum % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -19.56 vs LSE:BELL: -92.68

Belluscura  (LSE:BELL) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Belluscura 12-1 Month Momentum % Related Terms

LSE:BELL vs ABT, BSX, SYK: 12-1 Month Momentum % Comparison

For the Medical Devices subindustry, Belluscura's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belluscura 12-1 Month Momentum % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Belluscura's 12-1 Month Momentum % falls into.


Belluscura  (LSE:BELL) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -92.68% mean?
Belluscura (LSE:BELL) has a 12-1 Month Momentum % of -92.68% as of Aug. 30, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Belluscura and its competitors.
Is Belluscura's 12-1 Month Momentum % too high?
Belluscura's current 12-1 Month Momentum % is -92.68%.
How does Belluscura's 12-1 Month Momentum % compare to ABT and BSX?
Belluscura's 12-1 Month Momentum % of -92.68% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Belluscura and its competitors. Belluscura's current 12-1 Month Momentum % is -92.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current 12-1 Month Momentum % of -92.68%. The current 12-1 Month Momentum % is -92.68%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current 12-1 Month Momentum % is -92.68% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.